MARKET

FBT

FBT

First Trust NYSE Arca Biotech ETF
NYSEARCA

Real-time Quotes | Provided by Morningstar

162.43
-0.03
-0.02%
Closed 16:00 04/16 EDT
OPEN
163.14
PREV CLOSE
162.46
HIGH
163.18
LOW
161.58
VOLUME
75.00K
TURNOVER
--
52 WEEK HIGH
186.51
52 WEEK LOW
140.06
TOTAL ASSET
1.91B
YTD YIELD
3.93%
1D
5D
1M
3M
1Y
5Y
ETF Market Outlook & Picks for 2021
Zacks.com · 01/08 05:39
Bond Traders Lean Toward Higher Yields Amid Georgia Runoff
Bloomberg · 01/05 20:29
Markets Brace for Greater Chance of Blue Wave in Georgia Races
While the relentless spread of the coronavirus drove the equity market lower on Monday, there were also signs investors are preparing for a greater possibility that Democrats will gain control of the U.S. Senate.
Bloomberg · 01/04 21:04
Crypto Fund’s Price Diverges From Holdings in Latest Mispricing
Bloomberg · 01/04 19:49
ETFs’ Big Three Struggle to Make Mark in 2020’s Largest Launches
Three big players have long made up the majority of the $5.4 trillion U.S. exchange-traded fund industry, but their latest offerings were also-rans in a record year for new product launches.
Bloomberg · 01/04 16:10
China ADRs Fall as U.S. Ramps Up Pressure on Delisting Effort
Chinese stocks listed in the U.S., including China Telecom Corp. and Pinduoduo Inc., fell on the prospect of further sanctions that would remove more of the Asian nation’s biggest companies from American stock exchanges.
Bloomberg · 01/04 15:10
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a
Benzinga · 12/14/2020 13:29
Biotech Investing In A Time Of The Coronavirus
A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.
Seekingalpha · 10/09/2020 16:49
More
No Data
Learn about the latest financial forecast of FBT. Analyze the recent business situations of First Trust NYSE Arca Biotech ETF through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
Ratings
Date
Period
Agency
Ratings
08/31/2020
3 Year
Morningstar
08/31/2020
5 Year
Morningstar
08/31/2020
10 Year
Morningstar
  • Performance
  • Asset Allocation
  • Dividend History
Period
Return
Rank in Cat
1-Day
-3.3914%
--
1-Week
-1.5530%
--
1-Month
-9.1294%
--
3-Month
-6.4926%
--
6-Month
7.4838%
--
YTD
3.9307%
--
1-Year
23.0745%
--
3-Year
7.3855%
--
5-Year
6.7791%
--
10-Year
16.4213%
--
Since Inception
15.5934%
--
No Data
No Data
  • All
No Data
Profile
Fund Name
First Trust NYSE Arca Biotech ETF
Risk
Low risk
Inception Date
2006-06-19
Benchmark
Dow Jones US Healthcare TR
Advisor Company
First Trust
Custodian
The Bank of New York Mellon
Manager
Team Managed